For patients with intermediate-risk, localized prostate cancer, radiation therapy delivered in five sessions reduced patient-reported side effects compared to longer courses of radiation, according to ...

Physicians and scientists from the UCLA Health Jonsson Comprehensive Cancer Center will share the latest research and clinical trial results at the 2025 American Society for Radiation Oncology (ASTRO) ...

SAN FRANCISCO, September 29, 2025 — For patients with intermediate-risk, localized prostate cancer, radiation therapy delivered in five sessions reduced patient-reported side effects compared to ...

For men with the return of prostate cancer, a novel combined treatment can potentially give them an extended period before the cancer comes back. Researchers at UCLA have found that a blend of a ...

The phase 3 NRG GU-005 trial did not show a DFS benefit for SBRT vs IMRT in intermediate-risk prostate cancer, but SBRT decreased rectal toxicity. Stereotactic body radiation therapy (SBRT) preserves ...

In men with localized, intermediate-risk prostate cancer, stereotactic body radiation therapy (SBRT) was associated with less toxicity at 2 years but a higher rate of biochemical failure at 3 years ...

Stereotactic body radiotherapy (SBRT) showed good local control and survival for limited metastatic/progressive cancers. Two-thirds of patients were alive at 2 years with minimal serious toxicity ...

Please provide your email address to receive an email when new articles are posted on . Men assigned SBRT reported fewer adverse effects, but longer radiation courses may offer better biochemical ...

Docetaxel with androgen deprivation therapy (ADT) and radiotherapy (RT) for high-risk localized prostate cancer (HRLPC): An ICECaP individual patient-data (IPD) meta-analysis of randomized controlled ...

Physicians and scientists from the UCLA Health Jonsson Comprehensive Cancer Center will share the latest research and clinical trial results at the 2025 American Society for Radiation Oncology (ASTRO) ...

In men with hormone-sensitive metachronous oligometastatic prostate cancer, the use of stereotactic body radiotherapy (SBRT) commonly delayed the need for long-term ADT and provided durable disease ...

FRIDAY, Oct. 3, 2025 (HealthDay News) -- For patients with intermediate-risk localized prostate cancer, stereotactic body radiation therapy (SBRT) yields favorable bowel health-related quality of life ...